Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis cure 21 + lactobacillus plantarum 299
- Development stage
- Discontinued
- Lead developer
- Probi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination probiotic product containing two specific live bacterial strains: *Lactobacillus plantarum* 299 (also known as Lp299v) and *Bifidobacterium infantis* Cure 21. It is classified as a biologic therapy and was investigated in a randomized, double-blind, placebo-controlled trial for patients with poor ileal pouch function following proctocolectomy for ulcerative colitis. [2] The proposed mechanism involves modulating the gut microbiome to reduce inflammation and improve intestinal function. However, the pivotal study did not demonstrate a significant benefit over placebo in improving pouch functional scores or inflammation markers, and the hypothesis that it improves pouch-related dysfunction was not confirmed. [2, 4, 7] The *Lactobacillus plantarum* 299v strain is developed by Probi AB. [10]
- Other names
- Lactobacillus plantarum 299 and Bifidobacterium infantis Cure 21
02
Targets
AJC (Intestinal epithelial junctional complex)
Beyond the preview
Go deeper on bifidobacterium infantis cure 21 + lactobacillus plantarum 299.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis cure 21 + lactobacillus plantarum 299.